<DOC>
	<DOCNO>NCT01068509</DOCNO>
	<brief_summary>The purpose study determine safety efficacy investigational therapeutic agent ( Cvac ) ovarian cancer patient first second remission determine ability prevent cancer return . Study objectives Primary objective : - To confirm safety administer Cvac population . - To determine effect Cvac progression-free survival ( PFS ) . Secondary objective : - To determine overall survival ( OS ) ovarian cancer patient receive Cvac achieve remission first second-line setting . - Evaluation host immunologic response Cvac administration .</brief_summary>
	<brief_title>Ovarian Cancer Vaccine Patients Remission</brief_title>
	<detailed_description>An initial cohort 7 patient treated Cvac open-label phase confirm safety consistency manufacture Cvac drug product manufacture United States ( US ) Australia . After manufacture characteristic Cvac confirm consistent patient initial cohort complete 1 injection cycle Cvac serious treatment-related Grade 3 4 adverse event ( AEs ) , 56 patient enrol randomize ( 1:1 ) either Cvac observational standard care ( OSC ) .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<criteria>Female subject ≥ 18 year old histologically confirm Stage III IV epithelial ovarian , primary peritoneal fallopian tube cancer previously undergone surgical cytoreduction receive first second line conventional chemotherapy currently complete remission ( base clinical radiologic study ) . Cancer antigen ( CA ) 125 ≤ upper limit normal prior history elevate CA125 . Able willing undergo mononuclear cell collection . Not 12 week enrollment last dose chemotherapy result complete remission . No prior surgery peritoneum pleural space within 28 day enrollment , exclude removal catheter use chemotherapy administration . No prior treatment investigational product within 30 day enrollment . Baseline electrocardiogram within normal limit abnormality deem indicative cardiac disease intervention require . Serum creatinine ≤ 2 mg/dL . Serum aspartate aminotransferase serum alanine aminotransferase ≤ 2.5x upper limit normal serum total bilirubin ≤ 1.5x upper limit normal . White blood cell count ≥ 3.0 K/µL ; absolute neutrophil count ≥ 1.5K/µL ; hemoglobin ≥ 9.0 g/dL , platelet ≥ 100,000/mm^3 . ( These complete blood count result require enrollment . It note complete blood count result , include monocyte count ≥ 0.2 × 10^9/L , need prior leukapheresis determine sufficient dendritic cell obtain Cvac™ manufacture . ) Life expectancy least 12 month . Eastern Cooperative Oncology Group Performance Status 01 . All toxicity prior therapy , exclude alopecia , must resolve Common Terminology Criteria Adverse Events Grade ≤ 1 . Must nonpregnant , childbearing potential , must use adequate birth control ( hormonal barrier method birth control abstinence ) duration study 3 month study completion . Able provide write informed consent . Coexisting malignancy unless complete remission le 3 year . Does include situ carcinoma cervix basal cell squamous cell carcinoma skin restriction apply , assume adequately treat . Ovarian germ cell , sarcoma , mixed Mullerian tumor . Prior cancer vaccine cellular therapy . Active uncontrolled infection organ system toxicity ≥ Grade 2 Common Terminology Criteria Adverse Events criterion . Inability provide inform consent comply studyrelated procedure . Concurrent systemic treatment steroid immunosuppressive agent . Diagnosed immunodeficiency and/or autoimmune disorder . Myocardial infarction past 6 month and/or clinically significant heart disease . Infection human immunodeficient virus ( HIV ) , hepatitis B C virus . Pregnant breastfeeding . Evidence history central nervous system metastasis . Full dose anticoagulation therapy administer within 7 day leukapheresis procedure . Hematopoietic growth factor administer within 14 day enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cvac</keyword>
</DOC>